SCHEMBL3497767

SCHEMBL3497767

Cc1cc(C)cc(Nc2ncc(F)c(NC3CC(C)(C)N(C)C(C)(C)C3)n2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCQ Q04759 2/20 0.62
AURKA O14965 7/20 0.49
BTK Q06187 3/20 0.41
EGFR P00533 3/20 0.41
SYK P43405 10/20 0.40
KDR P35968 2/20 0.40
AURKB Q96GD4 2/20 0.40
ITK Q08881 2/20 0.40
PLK4 O00444 1/20 0.40
PDPK1 O15530 1/20 0.40
JAK2 O60674 1/20 0.40
PRKD3 O94806 1/20 0.40
MAP4K4 O95819 1/20 0.40
NTRK1 P04629 1/20 0.40
INSR P06213 1/20 0.40
LCK P06239 1/20 0.40
FYN P06241 1/20 0.40
CDK1 P06493 1/20 0.40
FES P07332 1/20 0.40
CSF1R P07333 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3495009 0.90 PRKCQ (0.61) PRKCQAURKABTKEGFRSYK
SCHEMBL3493194 0.90 PRKCQ (0.61) PRKCQAURKABTKEGFRSYK
SCHEMBL3494857 0.89 PRKCQ (0.50) PRKCQAURKAEGFRSYKKDR
SCHEMBL3496512 0.88 PRKCQ (0.59) PRKCQAURKABTKEGFRSYK
SCHEMBL3497300 0.88 PRKCQ (0.59) PRKCQAURKABTKEGFRSYK
SCHEMBL1741176 0.87 PRKCQ (0.63) PRKCQAURKABTKEGFRSYK
SCHEMBL3494249 0.86 PRKCQ (0.65) PRKCQAURKABTKEGFRSYK
SCHEMBL3492920 0.86 PRKCQ (0.75) PRKCQAURKABTKEGFRSYK
SCHEMBL3496410 0.86 PRKCQ (0.57) PRKCQBTKEGFRKDRAURKB
SCHEMBL3495899 0.86 PRKCQ (0.59) PRKCQAURKABTKEGFRSYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. 2010-05-27 US claimed
US-8993585-B2 Cyclic amine substituted pyrimidinediamines as PKC inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2015-03-31 US disclosed
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. 2010-05-27 US disclosed
EP-2183225-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2010-05-12 EP disclosed
WO-2009012421-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS PRKCH, PKD2, PRKCQ PRKCQ 3/4885AURKA 495/4885BTK 97/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.